AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

KPTI · NASDAQ · Biotechnology

Karyopharm Therapeutics (KPTI)

Commercializer of the XPO1 inhibitor selinexor for blood cancers.

$1.78

Pre-market0.00 (0.00%)

At close$1.78(−3.78%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	36	34	33	43	39	31	30	38	44	34	35	33
Cost of revenue	1	2	2	2	1	1	1	1	2	1	1	1
Gross profit	35	32	31	41	37	29	29	37	42	33	34	32
	66	70	65	69	64	60	62	61	57	50	60	55
Research & development	36	39	35	38	36	33	35	33	31	28	34	30
	31	31	30	31	28	27	27	28	27	23	27	26
General & administrative	31	31	30	31	28	27	27	28	27	23	27	26
Other expenses	0	0	0	0	0	0	0	0	0	0	0	−1
Operating income	−31	−38	−34	−28	−26	−31	−33	−24	−15	−18	−27	−23
	−3	−4	−4	52	−6	0	10	−13	−18	−84	4	−44
Interest income	3	3	2	2	2	1	1	1	1	1	1	1
Interest expense	6	6	6	9	11	11	11	11	11	13	13	13
Other non-operating income	−3	−2	−2	−61	−6	−12	−21	2	7	72	−17	31
Income before tax	−34	−42	−37	24	−32	−31	−23	−37	−33	−102	−22	−67
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−35	−42	−37	24	−32	−31	−23	−37	−33	−102	−22	−67
Net income	−35	−42	−37	24	−32	−31	−23	−37	−33	−102	−22	−67
EPS, basic	−$4.52	−$5.47	−$4.85	−$3.79	−$3.85	$2.81	−$2.77	−$4.32	−$3.82	−$15.16	−$1.02	−$2.32
EPS, diluted	−$4.52	−$5.47	−$4.85	−$2.97	−$3.85	$2.81	−$2.77	−$4.32	−$3.82	−$5.69	−$1.24	−$2.32
Weighted average shares, basic	8	8	8	8	8	8	8	9	9	7	22	29
Weighted average shares, diluted	8	8	8	10	8	8	8	9	9	18	25	29
EBITDA	−28	−35	−31	33	−21	−20	−12	−26	−23	−90	−10	−54
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−28	−35	−31	33	−21	−20	−12	−26	−23	−90	−10	−54